Following are the notable big biotech gainers on Monday:-
Verastem Inc (NASDAQ: VSTM) was the notable gainer and soared 24.76% after the company announced the FDA granted Breakthrough Therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, its FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy.
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) stock gained over 21% to $16.97 after it was upgraded from underperform to outperform by Bernstein analyst Alaxia Howard. Although it is true that the coronavirus pandemic eroded Beyond Meat sales both at home and abroad, Howard stated that the growth story is not yet over. The plans to utilize the funds to commence translation of the gene-editing, cellular therapy, and nanolipid particle platform into its emerging clinical programs with a focus on orphan diseases like sickle cell anemia, familial amyloidosis, and cell therapies for cancer.
Aptorum Group Ltd (NASDAQ: APM) was up 17.65% to close at $2.80. The company announces positive progress in respect of: (i) its ongoing Phase I clinical trial for ALS-4 (a first in-class anti-virulence approach based small molecule targeting Staphylococcus aureus, including, but not limited to Methicillin Resistant Staphylococcus Aureus (“MRSA”)), under which two initial cohorts of the single dose ascending dose (SAD) portion of the trial in healthy male and female adult subjects have been completed.
